Amended FDA Protocol Submitted for Phase 2b Trial of Advanced Alzheimer’s Therapy
Neurotrope BioScience has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of its lead product candidate bryostatin-1 for treating advanced Alzheimer’s disease. The company said in a press release that in the original trial protocol, the primary efficacy outcome is…